OpenURL Connection Search

Select item for more details and to access through your institution.

Protein kinase C α and δ are members of a large kinase family of high potential for novel anticancer targeted therapy.
Published in:
Targeted Oncology, 2006, v. 1, n. 1, p. 42, doi. 10.1007/s11523-005-0003-0
By:
- Ghoul, A.;
- Serova, M.;
- Benhadji, K.;
- Cvitkovic, E.;
- Faivre, S.;
- Philips, E.;
- Calvo, F.;
- Lokiec, F.;
- Raymond, E.
Publication type:
Article
Safety and clinical activity of the Notch inhibitor, crenigacestat (LY3039478), in an open-label phase I trial expansion cohort of advanced or metastatic adenoid cystic carcinoma.
Published in:
2020
By:
- Even, C.;
- Lassen, U.;
- Merchan, J.;
- Le Tourneau, C.;
- Soria, J-C;
- Ferte, C.;
- Ricci, F.;
- Diener, J. T.;
- Yuen, E.;
- Smith, C.;
- Oakley III, G. J.;
- Benhadji, K. A.;
- Massard, Christophe
Publication type:
Calendar
A bulky single mass of the liver that revealed a primary hepatic leiomyosarcoma.
Published in:
Oncologie (Tech Science Press), 2006, v. 8, n. 10, p. 927, doi. 10.1007/s10269-006-0516-x
By:
- El Mesbahi, O.;
- Benhadji, K.;
- Paradis, V.;
- Belghiti, J.;
- Misset, J.-L.;
- Raymond, E.
Publication type:
Article
Antiproliferative activity of PEP005, a novel ingenol angelate that modulates PKC functions, alone and in combination with cytotoxic agents in human colon cancer cells.
Published in:
2008
By:
- Benhadji, K. A.;
- Serova, M.;
- Ghoul, A.;
- Cvitkovic, E.;
- Le Tourneau, C.;
- Ogbourne, S. M.;
- Lokiec, F.;
- Calvo, F.;
- Hammel, P.;
- Faivre, S.;
- Raymond, E.
Publication type:
journal article
A phase 1b study of crenigacestat (LY3039478) in combination with gemcitabine and cisplatin or gemcitabine and carboplatin in patients with advanced or metastatic solid tumors.
Published in:
2022
By:
- Massard, C.;
- Cassier, P. A.;
- Azaro, A.;
- Anderson, B.;
- Yuen, E.;
- Yu, D.;
- Oakley III, G.;
- Benhadji, K. A.;
- Pant, S.;
- Oakley, G 3rd
Publication type:
journal article
The serine-threonine kinase p90RSK is a new target of enzastaurin in follicular lymphoma cells.
Published in:
British Journal of Pharmacology, 2013, v. 170, n. 7, p. 1374, doi. 10.1111/bph.12351
By:
- Kheirallah, S;
- Fruchon, S;
- Ysebaert, L;
- Blanc, A;
- Capilla, F;
- Marrot, A;
- AlSaati, T;
- Frenois, F X;
- Benhadji, K A;
- Fournié, J J;
- Laurent, G;
- Bezombes, C
Publication type:
Article
Antiproliferative effects of sapacitabine (CYC682), a novel 2′-deoxycytidine-derivative, in human cancer cells.
Published in:
British Journal of Cancer, 2007, v. 97, n. 5, p. 628, doi. 10.1038/sj.bjc.6603896
By:
- Serova, M;
- Galmarini, C M;
- Ghoul, A;
- Benhadji, K;
- Green, S R;
- Chiao, J;
- Faivre, S;
- Cvitkovic, E;
- Le Tourneau, C;
- Calvo, F;
- Raymond, E
Publication type:
Article

Found: 7

Protein kinase C α and δ are members of a large kinase family of high potential for novel anticancer targeted therapy.

Safety and clinical activity of the Notch inhibitor, crenigacestat (LY3039478), in an open-label phase I trial expansion cohort of advanced or metastatic adenoid cystic carcinoma.

A bulky single mass of the liver that revealed a primary hepatic leiomyosarcoma.

Antiproliferative activity of PEP005, a novel ingenol angelate that modulates PKC functions, alone and in combination with cytotoxic agents in human colon cancer cells.

A phase 1b study of crenigacestat (LY3039478) in combination with gemcitabine and cisplatin or gemcitabine and carboplatin in patients with advanced or metastatic solid tumors.

The serine-threonine kinase p90RSK is a new target of enzastaurin in follicular lymphoma cells.

Antiproliferative effects of sapacitabine (CYC682), a novel 2′-deoxycytidine-derivative, in human cancer cells.